Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 11, 2017, Pages 2678-2687

  Liu, Chao ^a   Gao, Haiyan ^a   Lv, Peng ^a   Liu, Jingyi ^a   Liu, Gang ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

cancer; clinical translation; drug delivery system; extracellular vesicles

Indexed keywords

CD40 LIGAND; CD63 ANTIGEN; CHOLINERGIC RECEPTOR; CURCUMIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN IIB; INTEGRIN; PHOSPHATIDYLSERINE; SELECTIN; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; TETRASPANIN; NANOMATERIAL; PROTEIN;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER SUSCEPTIBILITY; COLON CANCER; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENCAPSULATION; EXOSOME; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MESENCHYMAL STEM CELL; MUCOSA INFLAMMATION; MULTIVESICULAR BODY; NANOMEDICINE; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; ANIMAL; CHEMISTRY; MOUSE; NANOTECHNOLOGY; NEOPLASM; PROCEDURES; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR VESICLES; HUMANS; MICE; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS; PROTEINS;

EID: 85034775164     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1363935     Document Type: Review

References (126)

1. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36:43-8. doi:10.1177/0192623307310946. PMID:18337220
2. Nazar MF, Khan AM, Shah SS. Microemulsion system with improved loading of piroxicam: A study of microstructure. AAPS Pharmscitech. 2009;10:1286-94. doi:10.1208/s12249-009-9328-9. PMID:19876741
3. Wei T, Liu J, Ma H, Cheng Q, Huang Y, Zhao J, Huo S, Xue X, Liang Z, Liang XJ. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 2013;13:2528-34. doi:10.1021/nl400586t. PMID:23634882
4. Dang YJ, Zhu CY. Oral bioavailability of cantharidin-loaded solid lipid nanoparticles. Chin Med. 2013;8:1. doi:10.1186/1749-8546-8-1. PMID:23298453
5. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA, Navari RM, Bilgicer B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012;2:e64. doi:10.1038/bcj.2012.10. PMID:22829966
6. Azzi J, Tang L, Moore R, Tong R, El HN, Akiyoshi T, Mfarrej B, Yang S, Jurewicz M, Ichimura T, et al. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 2010;24:3927-38. doi:10.1096/fj.10-154690. PMID:20547662
7. Abd-Allah FI, Dawaba HM, Ahmed AM. Development of a microemulsion-based formulation to improve the availability of poorly water-soluble drug. Drug Discov Ther. 2010;4:257-66. PMID:22491208
8. Jesson G, Brisander M, Andersson P, Demirbuker M, Derand H, Lennernas H, Malmsten M. Carbon dioxide-mediated generation of hybrid nanoparticles for improved bioavailability of protein kinase inhibitors. Pharm Res. 2014;31:694-705. doi:10.1007/s11095-013-1191-4. PMID:23990314
9. Dwivedi P, Khatik R, Khandelwal K, Taneja I, Raju KS, Wahajuddin, Paliwal SK, Dwivedi AK, Mishra PR. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: An improved oral bioavailability in rats. Int J Pharm. 2014;466:321-7. doi:10.1016/j.ijpharm.2014.03.036. PMID:24657144
10. Singh G, Pai RS. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv. 2014;11:647-59. doi:10.1517/17425247.2014.890588. PMID:24661109
11. Joshi G, Kumar A, Sawant K. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci. 2014;60:80-9. doi:10.1016/j.ejps.2014.04.014. PMID:24810394
12. Chen JP, Yang PC, Ma YH, Tu SJ, Lu YJ. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. Int J Nanomedicine. 2012;7:5137-49. doi:10.2147/IJN.S36197. PMID:23055726
13. Amaral AC, Bocca AL, Ribeiro AM, Nunes J, Peixoto DL, Simioni AR, Primo FL, Lacava ZG, Bentes R, Titze-De-Almeida R, et al. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J Antimicrob Chemother. 2009;63:526-33. doi:10.1093/jac/dkn539. PMID:19151037
14. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA, Navari RM, Bilgicer B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012;2:e64. doi:10.1038/bcj.2012.10. PMID:22829966
15. Casa DM, Carraro TC, de Camargo LE, Dalmolin LF, Khalil NM, Mainardes RM. Poly(L-lactide) nanoparticles reduce amphotericin B cytotoxicity and maintain its in vitro antifungal activity. J Nanosci Nanotechnol. 2015;15:848-54. doi:10.1166/jnn.2015.9177. PMID:26328449
16. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64:1020-37. doi:10.1016/S1734-1140(12)70901-5. PMID:23238461
17. Zhang J, Liang YC, Lin X, Zhu X, Yan L, Li S, Yang X, Zhu G, Rogach AL, Yu PK, et al. Self-monitoring and self-delivery of photosensitizer-doped nanoparticles for highly effective combination cancer therapy in Vitro and in Vivo. ACS Nano. 2015;9:9741-56. doi:10.1021/acsnano.5b02513. PMID:26390118
18. Zhang J, Li S, An FF, Liu J, Jin S, Zhang JC, Wang PC, Zhang X, Lee CS, Liang XJ. Self-carried curcumin nanoparticles for in vitro and in vivo cancer therapy with real-time monitoring of drug release. Nanoscale. 2015;7:13503-10. doi:10.1039/C5NR03259H. PMID:26199064
19. Bale S, Khurana A, Reddy AS, Singh M, Godugu C. Overview on therapeutic applications of microparticulate drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2016;33:309-61. doi:10.1615/CritRevTherDrugCarrierSyst.2016015798. PMID:27910739
20. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology. 2010;151:458-65. doi:10.1210/en.2009-1082. PMID:20016026
21. Ray PC, Yu H, Fu PP. Toxicity and environmental risks of nanomaterials: Challenges and future needs. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27:1-35. doi:10.1080/10590500802708267. PMID:19204862
22. Dhawan A, Sharma V. Toxicity assessment of nanomaterials: Methods and challenges. Anal Bioanal Chem. 2010;398:589-605. doi:10.1007/s00216-010-3996-x. PMID:20652549
23. Shukla S, Arora V, Jadaun A, Kumar J, Singh N, Jain VK. Magnetic removal of Entamoeba cysts from water using chitosan oligosaccharide-coated iron oxide nanoparticles. Int J Nanomedicine. 2015;10:4901-17. doi:10.2147/IJN.S77675. PMID:26261417
24. Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, Nair JK, Akinc A, Barros SA, Kasperkovitz PV. Shielding of lipid nanoparticles for siRNA delivery: Impact on physicochemical properties, cytokine induction, and efficacy. Mol Ther Nucleic Acids. 2014;3:e210. doi:10.1038/mtna.2014.61. PMID:25405467
25. Chan VS. Nanomedicine: An unresolved regulatory issue. Regul Toxicol Pharmacol. 2006;46:218-24. doi:10.1016/j.yrtph.2006.04.009. PMID:17081666
26. El-Ansary A, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: An overview. J Toxicol. 2009;2009:754810. doi:10.1155/2009/754810. PMID:20130771
27. Mogharabi M, Abdollahi M, Faramarzi MA. Toxicity of nanomaterials; an undermined issue. DARU. 2014;22:59. doi:10.1186/s40199-014-0059-4. PMID:25123555
28. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113:1-11. doi:10.1007/s11060-013-1084-8. PMID:23456661
29. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: Cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836-48. doi:10.1016/j.ccell.2016.10.009. PMID:27960084
30. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: A novel class of drug delivery systems. Int J Nanomedicine. 2012;7:1525-41. PMID:22619510
31. El AS, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347-57. doi:10.1038/nrd3978. PMID:23584393
32. Lee J, Lee H, Goh U, Kim J, Jeong M, Lee J, Park JH. Cellular engineering with membrane fusogenic liposomes to produce functionalized extracellular vesicles. ACS Appl Mater Interfaces. 2016;8:6790-5. doi:10.1021/acsami.6b01315. PMID:26954538
33. Armstrong JP, Holme MN, Stevens MM. Re-Engineering extracellular vesicles as smart nanoscale therapeutics. ACS Nano. 2017;11:69-83. doi:10.1021/acsnano.6b07607. PMID:28068069
34. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581-93. doi:10.1038/nri2567. PMID:19498381
35. Kalra H, Drummen GP, Mathivanan S. Focus on extracellular vesicles: Introducing the next small big thing. Int J Mol Sci. 2016;17:170. doi:10.3390/ijms17020170. PMID:26861301
36. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:3-22.
37. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262:9412-20. PMID:3597417
38. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B, Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244-7. doi:10.1126/science.1153124. PMID:18309083
39. Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim Biophys Acta. 2014;1841:108-20. doi:10.1016/j.bbalip.2013.10.004. PMID:24140720
40. Simpson RJ, Kalra H, Mathivanan S. ExoCarta as a resource for exosomal research. J Extracell Vesicles. 2012;1:24009883. doi:10.3402/jev.v1i0.18374
41. van Doormaal FF, Kleinjan A, Di Nisio M, Buller HR, Nieuwland R. Cell-derived microvesicles and cancer. Neth J Med. 2009;67:266-73.
42. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: Shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012;26:1287-99. doi:10.1101/gad.192351.112. PMID:22713869
43. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1:98-110. PMID:21969178
44. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: Artefacts no more. Trends Cell Biol. 2009;19:43-51. doi:10.1016/j.tcb.2008.11.003. PMID:19144520
45. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166:7309-18. doi:10.4049/jimmunol.166.12.7309. PMID:11390481
46. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255-89. doi:10.1146/annurev-cellbio-101512-122326. PMID:25288114
47. Wang GJ, Liu Y, Qin A, Shah SV, Deng ZB, Xiang X, Cheng Z, Liu C, Wang J, Zhang L, et al. Thymus exosomes-like particles induce regulatory T cells. J Immunol. 2008;181:5242-8. doi:10.4049/jimmunol.181.8.5242. PMID:18832678
48. Fan GC. Hypoxic exosomes promote angiogenesis. Blood. 2014;124:3669-70. doi:10.1182/blood-2014-10-607846. PMID:25498451
49. Baragano RA, Suarez-Alvarez B, Lopez-Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. OncoImmunology. 2014;3:e28497. doi:10.4161/onci.28497. PMID:25050215
50. Baixauli F, Lopez-Otin C, Mittelbrunn M. Exosomes and autophagy: Coordinated mechanisms for the maintenance of cellular fitness. Front Immunol. 2014;5:403. doi:10.3389/fimmu.2014.00403. PMID:25191326
51. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014;348:71-6. doi:10.1016/j.canlet.2014.03.009. PMID:24657661
52. Ailawadi S, Wang X, Gu H, Fan GC. Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta. 2015;1852:1-11. doi:10.1016/j.bbadis.2014.10.008. PMID:25463630
53. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26:707-21. doi:10.1016/j.ccell.2014.09.005. PMID:25446899
54. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555-66. doi:10.1182/blood-2014-03-562439. PMID:24928860
55. Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: A busy sorting station for proteins at the crossroads. Histol Histopathol. 2010;25:99-112. PMID:19924646
56. Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:442. doi:10.3389/fimmu.2014.00442. PMID:25278937
57. Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Sorting it out: Regulation of exosome loading. Semin Cancer Biol. 2014;28:3-13. doi:10.1016/j.semcancer.2014.04.009. PMID:24769058
58. Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Thery C, Raposo G. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126:5553-65. doi:10.1242/jcs.128868. PMID:24105262
59. Stuffers S, Sem WC, Stenmark H, Brech A. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic. 2009;10:925-37. doi:10.1111/j.1600-0854.2009.00920.x. PMID:19490536
60. Sadallah S, Eken C, Schifferli JA. Ectosomes as modulators of inflammation and immunity. Clin Exp Immunol. 2011;163:26-32. doi:10.1111/j.1365-2249.2010.04271.x. PMID:21039423
61. Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396-405. doi:10.1016/j.jconrel.2015.07.030. PMID:26241750
62. van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug delivery systems: Lessons from the liposome field. J Control Release. 2014;195:72-85. doi:10.1016/j.jconrel.2014.07.049. PMID:25094032
63. Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9:e1450. doi:10.1002/wnan.1450. PMID:28198148.
64. Chang HI, Yeh MK. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49-60. PMID:22275822
65. van Dommelen SM, Vader P, Lakhal S, Kooijmans SA, van Solinge WW, Wood MJ, Schiffelers RM. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. J Control Release. 2012;161:635-44. doi:10.1016/j.jconrel.2011.11.021. PMID:22138068
66. El AS, Lakhal S, Mager I, Wood MJ. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev. 2013;65:391-7. doi:10.1016/j.addr.2012.08.008. PMID:22921840
67. Kosaka N, Takeshita F, Yoshioka Y, Hagiwara K, Katsuda T, Ono M, Ochiya T. Exosomal tumor-suppressive microRNAs as novel cancer therapy: “exocure” is another choice for cancer treatment. Adv Drug Deliv Rev. 2013;65:376-82. doi:10.1016/j.addr.2012.07.011. PMID:22841506
68. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341-5. doi:10.1038/nbt.1807. PMID:21423189
69. Jiang XC, Gao JQ. Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm. 2017;521:167-75. doi:10.1016/j.ijpharm.2017.02.038. PMID:28216464
70. Barile L, Vassalli G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63-78. doi:10.1016/j.pharmthera.2017.02.020. PMID:28202367
71. Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J Control Release. 2012;164:138-44. doi:10.1016/j.jconrel.2012.04.038. PMID:22595146
72. Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Strobel T, Breakefield XO, Saydam O. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther. 2013;21:101-8. doi:10.1038/mt.2012.161. PMID:22910294
73. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21:185-91. doi:10.1038/mt.2012.180
74. Zhang Y, Li L, Yu J, Zhu D, Zhang Y, Li X, Gu H, Zhang CY, Zen K. Microvesicle-mediated delivery of transforming growth factor beta1 siRNA for the suppression of tumor growth in mice. Biomaterials. 2014;35:4390-400. doi:10.1016/j.biomaterials.2014.02.003. PMID:24565517
75. Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O, Shu W, Jiang F, Chopp M. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013;335:201-4. doi:10.1016/j.canlet.2013.02.019. PMID:23419525
76. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2013;2:e126. doi:10.1038/mtna.2013.60. PMID:24084846
77. Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Strobel T, Erkan EP, Fan JB, Breakefield XO, Saydam O. miR-1289 and “Zipcode”-like sequence enrich mRNAs in microvesicles. Mol Ther Nucleic Acids. 2012;1:e10. doi:10.1038/mtna.2011.2. PMID:23344721
78. Gujrati V, Kim S, Kim SH, Min JJ, Choy HE, Kim SC, Jon S. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014;8:1525-37. doi:10.1021/nn405724x. PMID:24410085
79. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35:2383-90. doi:10.1016/j.biomaterials.2013.11.083. PMID:24345736
80. Jang SC, Kim OY, Yoon CM, Choi DS, Roh TY, Park J, Nilsson J, Lotvall J, Kim YK, Gho YS. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano. 2013;7:7698-710. doi:10.1021/nn402232g. PMID:24004438
81. Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, Lv M, Li D, Katirai F, Shen GX, et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3:1282. doi:10.1038/ncomms2282. PMID:23250412
82. Saari H, Lazaro-Ibanez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220:727-37. doi:10.1016/j.jconrel.2015.09.031. PMID:26390807
83. Guo F, Chang CK, Fan HH, Nie XX, Ren YN, Liu YY, Zhao LH. Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Int Med Res. 2008;36:1342-53. doi:10.1177/147323000803600623. PMID:19094445
84. Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Vigano L, Locatelli A, Sisto F, Doglia SM, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014;192:262-70. doi:10.1016/j.jconrel.2014.07.042. PMID:25084218
85. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303. doi:10.1038/85438. PMID:11231627
86. Shimoda A, Ueda K, Nishiumi S, Murata-Kamiya N, Mukai SA, Sawada S, Azuma T, Hatakeyama M, Akiyoshi K. Exosomes as nanocarriers for systemic delivery of the Helicobacter pylori virulence factor CagA. Sci Rep. 2016;6:18346. doi:10.1038/srep18346. PMID:26739388
87. Aspe JR, Diaz OC, Jutzy JM, Deshields S, Whang S, Wall NR. Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant. J Extracell Vesicles. 2014;3:24624263. doi:10.3402/jev.v3.23244
88. Buzas EI, Gyorgy B, Nagy G, Falus A, Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol. 2014;10:356-64. doi:10.1038/nrrheum.2014.19. PMID:24535546
89. Candelario KM, Steindler DA. The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. Trends Mol Med. 2014;20:368-74. doi:10.1016/j.molmed.2014.04.003. PMID:24835084
90. Gaceb A, Martinez MC, Andriantsitohaina R. Extracellular vesicles: New players in cardiovascular diseases. Int J Biochem Cell Biol. 2014;50:24-8. doi:10.1016/j.biocel.2014.01.018. PMID:24509128
91. Fleury A, Martinez MC, Le Lay S. Extracellular vesicles as therapeutic tools in cardiovascular diseases. Front Immunol. 2014;5:370. doi:10.3389/fimmu.2014.00370. PMID:25136343
92. Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017;14:259-72. doi:10.1038/nrcardio.2017.7. PMID:28150804
93. Chen L, Wang Y, Pan Y, Zhang L, Shen C, Qin G, Ashraf M, Weintraub N, Ma G, Tang Y. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun. 2013;431:566-71. doi:10.1016/j.bbrc.2013.01.015. PMID:23318173
94. Benameur T, Soleti R, Porro C, Andriantsitohaina R, Martinez MC. Microparticles carrying Sonic hedgehog favor neovascularization through the activation of nitric oxide pathway in mice. PLoS One. 2010;5:e12688. doi:10.1371/journal.pone.0012688. PMID:20856928
95. Soleti R, Benameur T, Porro C, Panaro MA, Andriantsitohaina R, Martinez MC. Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis. 2009;30:580-8. doi:10.1093/carcin/bgp030. PMID:19168578
96. Agouni A, Mostefai HA, Porro C, Carusio N, Favre J, Richard V, Henrion D, Martinez MC, Andriantsitohaina R. Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. FASEB J. 2007;21:2735-41. doi:10.1096/fj.07-8079com. PMID:17428963
97. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011;19:1769-79. doi:10.1038/mt.2011.164. PMID:21915101
98. Kalani A, Kamat PK, Chaturvedi P, Tyagi SC, Tyagi N. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci. 2014;107:1-7. doi:10.1016/j.lfs.2014.04.018. PMID:24780320
99. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18:1606-14. doi:10.1038/mt.2010.105. PMID:20571541
100. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005;174:6440-8. doi:10.4049/jimmunol.174.10.6440. PMID:15879146
101. Aline F, Bout D, Amigorena S, Roingeard P, Dimier-Poisson I. Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect Immun. 2004;72:4127-37. doi:10.1128/IAI.72.7.4127-4137.2004. PMID:15213158
102. Hoheisel G, Luk WK, Winkler J, Gillissen A, Wirtz H, Liebert UG, Hui DS. [Severe acute respiratory syndrome (SARS)]. Med Klin (Munich). 2006;101:957-63. doi:10.1007/s00063-006-1127-4. PMID:17171319
103. Kuate S, Cinatl J, Doerr HW, Uberla K. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology. 2007;362:26-37. doi:10.1016/j.virol.2006.12.011. PMID:17258782
104. Tominaga N, Yoshioka Y, Ochiya T. A novel platform for cancer therapy using extracellular vesicles. Adv Drug Deliv Rev. 2015;95:50-5. doi:10.1016/j.addr.2015.10.002. PMID:26482189
105. Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro DSA, Del PH, El AS, et al. Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano. 2016;10:3886-99. doi:10.1021/acsnano.5b08015. PMID:26978483
106. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst phase I clinical trial. J Transl Med. 2005;3:10. doi:10.1186/1479-5876-3-10. PMID:15740633
107. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9. doi:10.1186/1479-5876-3-9. PMID:15723705
108. Viaud S, Ploix S, Lapierre V, Thery C, Commere PH, Tramalloni D, Gorrichon K, Virault-Rocroy P, Tursz T, Lantz O, et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J Immunother. 2011;34:65-75. doi:10.1097/CJI.0b013e3181fe535b. PMID:21150714
109. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, Li G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 2008;16:782-90. doi:10.1038/mt.2008.1. PMID:18362931
110. Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol. 2007;14:1062-9. doi:10.1128/CVI.00094-07. PMID:17634513
111. van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. Biotechnol J. 2015;10:1689-706. doi:10.1002/biot.201400395. PMID:26912077
112. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-37. doi:10.1086/656741. PMID:20954968
113. Marsay L, Dold C, Green CA, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect. 2015;71:326-37. doi:10.1016/j.jinf.2015.05.006. PMID:25982025
114. James Graham Brown Cancer Center. Study investigating the ability of plant exosomes to deliver curcumin to normal and colon cancer tissue. 2011 Feb3 [accessed 2017Feb6]. https://www.clinicaltrials.gov/ct2/show/study/NCT01294072
115. James Graham Brown Cancer Center. Edible plant exosome ability to prevent oral mucositis associated with chemoradiation treatment of head and neck cancer. 2012 Aug 6 [accessed 2017Feb6[. https://clinicaltrials.gov/show/NCT01668849
116. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, Epple M, Horn PA, Beelen DW, Giebel B. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970-3. PMID:24445866
117. Leblanc P, Arellano-Anaya ZE, Bernard E, Gallay L, Provansal M, Lehmann S, Schaeffer L, Raposo G, Vilette D. Isolation of exosomes and microvesicles from cell culture systems to study prion transmission. Methods Mol Biol. 2017;1545:153-76. doi:10.1007/978-1-4939-6728-5_11. PMID:27943213
118. Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, Gho YS, Kurochkin IV, Mathivanan S, Quesenberry P, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the international society for extracellular vesicles. J Extracell Vesicles. 2014;3:26913. doi:10.3402/jev.v3.26913. PMID:25536934
119. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002;270:211-26. doi:10.1016/S0022-1759(02)00330-7. PMID:12379326
120. Lozano-Ramos I, Bancu I, Oliveira-Tercero A, Armengol MP, Menezes-Neto A, Del PH, Lauzurica-Valdemoros R, Borras FE. Size-exclusion chromatography-based enrichment of extracellular vesicles from urine samples. J Extracell Vesicles. 2015;4:27369. doi:10.3402/jev.v4.27369. PMID:26025625
121. Lunavat TR, Jang SC, Nilsson L, Park HT, Repiska G, Lasser C, Nilsson JA, Gho YS, Lotvall J. RNAi delivery by exosome-mimetic nanovesicles–Implications for targeting c-Myc in cancer. Biomaterials. 2016;102:231-8. doi:10.1016/j.biomaterials.2016.06.024. PMID:27344366
122. Zhang P, Chen Y, Zeng Y, Shen C, Li R, Guo Z, Li S, Zheng Q, Chu C, Wang Z, et al. Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc Natl Acad Sci U S A. 2015;112:E6129-38. doi:10.1073/pnas.1505799112. PMID:26504197
123. Mi P, Zhang P, Liu G. Bio-inspired virus-like nanovesicle for effective vaccination. Hum Vaccin Immunother. 2016;12:2090-1. doi:10.1080/21645515.2016.1157244. PMID:27141919
124. Zhang P, Liu G, Chen X. Nanobiotechnology: Cell membrane-based delivery systems. Nano Today. 2017;13:7-9. doi:10.1016/j.nantod.2016.10.008. PMID:28435439
125. Thomas Jefferson University Hospita. Pilot immunotherapy trial for recurrent malignant gliomas. 2012 Feb 14 ]accessed 2017Feb6]. https://www.clinicaltrials.gov/ct2/show/study/NCT01294072
126. Sahel Teaching Hospital. Effect of microvesicles and exosomes therapy on β-cell mass in type I diabetes mellitus (T1DM). 2014 May 12 [accessed 2017Feb6]. https://clinicaltrials.gov/show/NCT02138331